-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Center for Drug Evaluation (CDE) of the State Drug Administration of China announced that Teva's 5.
1 class new drug "Glatirar Acetate Injection" has submitted a marketing application in China and has been accepted
.
According to Teva’s financial report, glatiramer acetate injection (English trade name: Copaxone) is a multiple sclerosis (MS) drug with global sales of US$1.
Glatiramer acetate is a synthetic peptide compound composed of four amino acids including glutamic acid, alanine, tyrosine and lysine
.
It is thought to work by changing the immune process that causes the pathogenesis of MS
According to reports in the literature, an open study that has been conducted for 6 years shows that glatiramer acetate injection can alleviate the recurrence rate of patients with multiple sclerosis and reduce the rate of disease development
.
In this study, the researchers first conducted a placebo-controlled randomized trial on 251 patients, of which 208 patients voluntarily chose to continue the open trial in which all subjects received glatiramer acetate injection
The results showed that patients who received glatiramer acetate injection in both randomized and open trials had an average annual recurrence rate of 0.
42%
It is hoped that Teva's glatiramer acetate injection will be approved in China as soon as possible, bringing new treatment options to more patients with multiple sclerosis
.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options
.
If you need guidance on treatment plans, please go to a regular hospital for treatment
Reference materials:
Reference materials:[1] Drug Evaluation Center of China National Medical Products Administration.
[1] Drug Evaluation Center of China National Medical Products Administration.
[2] Teva Reports Fourth Quarter and Full Year 2014 Results.
[3] Ma Peiqi.
Copaxone is beneficial for long-term treatment of multiple sclerosis [J].
Foreign Medicine News, 2000: 27-28.
